MX371404B - Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). - Google Patents

Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Info

Publication number
MX371404B
MX371404B MX2017010363A MX2017010363A MX371404B MX 371404 B MX371404 B MX 371404B MX 2017010363 A MX2017010363 A MX 2017010363A MX 2017010363 A MX2017010363 A MX 2017010363A MX 371404 B MX371404 B MX 371404B
Authority
MX
Mexico
Prior art keywords
compounds
isochromanyl
heterocyclyl
analogs
cns disorders
Prior art date
Application number
MX2017010363A
Other languages
English (en)
Other versions
MX2017010363A (es
Inventor
G Hanania Taleen
ALEXANDROV Vadim
Xie Linghong
Glyn Jones Philip
L Spear Kerry
Aaron Powell Noel
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2017010363A publication Critical patent/MX2017010363A/es
Publication of MX371404B publication Critical patent/MX371404B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, en donde A, Ra R1, R2, R3, R4, R6, w y n1 se definen y describen en la presente; composiciones de los mismos; y métodos de uso de los mismos. Estos compuestos son útiles para tratar una variedad de trastornos neurológicos y psiquiátricos, tales como los descritos aquí.
MX2017010363A 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). MX371404B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Publications (2)

Publication Number Publication Date
MX2017010363A MX2017010363A (es) 2018-05-04
MX371404B true MX371404B (es) 2020-01-29

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010363A MX371404B (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2020001157A MX2020001157A (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001157A MX2020001157A (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Country Status (21)

Country Link
US (4) US9856238B2 (es)
EP (2) EP3256466B9 (es)
JP (3) JP6657241B2 (es)
KR (1) KR102601972B1 (es)
CN (2) CN107531674B (es)
AU (1) AU2016219253C1 (es)
CA (1) CA2976095C (es)
DK (1) DK3256466T3 (es)
EA (1) EA201791804A1 (es)
ES (2) ES2967643T3 (es)
HU (1) HUE058698T2 (es)
IL (1) IL253914B (es)
MX (2) MX371404B (es)
MY (1) MY188160A (es)
NZ (1) NZ735011A (es)
PH (1) PH12017501422A1 (es)
PL (1) PL3256466T3 (es)
PT (1) PT3256466T (es)
SG (2) SG10201806809QA (es)
UA (1) UA122222C2 (es)
WO (1) WO2016130796A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3256466T3 (pl) * 2015-02-11 2022-05-23 Sunovion Pharmaceuticals Inc. Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun
MX371197B (es) * 2015-02-11 2020-01-22 Sunovion Pharmaceuticals Inc Compuestos de dihidro-4h-pirazolo [5,1-c] [1,4] oxazinilo y análogos para el tratamiento de trastornos del sistema nervioso central (snc).
BR112019001439A8 (pt) * 2016-07-29 2019-11-12 Pgi Drug Discovery Llc compostos e composições e usos dos mesmos
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
WO2019028165A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. ISOCHROMAN COMPOUNDS AND USES THEREOF
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
CA2336254A1 (en) 1998-06-30 2000-01-06 Daniel James Koch 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
BR0213949A (pt) * 2001-11-08 2004-08-31 Sepracor Inc Métodos para o tratamento de depressão e outros distúrbios do snc utilizando metabólitos desmetila e didesmetila de citalopram enanciomericamente enriquecidos
EP1831203A1 (en) * 2004-12-21 2007-09-12 F. Hoffmann-Roche AG Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
RU2440344C2 (ru) * 2006-01-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг Применение 2-имидазолов для лечения расстройств цнс
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
KR101637247B1 (ko) * 2009-12-04 2016-07-07 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
CA2896871A1 (en) * 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
PL3256466T3 (pl) * 2015-02-11 2022-05-23 Sunovion Pharmaceuticals Inc. Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun

Also Published As

Publication number Publication date
CN111925360B (zh) 2024-03-22
CA2976095C (en) 2023-10-17
JP2022065050A (ja) 2022-04-26
ES2911910T9 (es) 2022-08-12
SG10201806809QA (en) 2018-09-27
EP3256466B9 (en) 2022-07-27
JP6657241B2 (ja) 2020-03-04
KR102601972B1 (ko) 2023-11-13
CN111925360A (zh) 2020-11-13
PH12017501422A1 (en) 2018-03-19
EP3256466A1 (en) 2017-12-20
WO2016130796A1 (en) 2016-08-18
EA201791804A1 (ru) 2018-02-28
US20170001987A1 (en) 2017-01-05
HUE058698T2 (hu) 2022-09-28
UA122222C2 (uk) 2020-10-12
MY188160A (en) 2021-11-24
EP4046995B1 (en) 2023-09-13
CN107531674A (zh) 2018-01-02
NZ735011A (en) 2023-07-28
IL253914A0 (en) 2017-10-31
AU2016219253C1 (en) 2022-12-08
ES2911910T3 (es) 2022-05-23
US20190389845A1 (en) 2019-12-26
EP4046995C0 (en) 2023-09-13
US20220185799A1 (en) 2022-06-16
EP3256466B1 (en) 2022-04-06
PL3256466T3 (pl) 2022-05-23
AU2016219253A1 (en) 2017-09-21
JP2020079282A (ja) 2020-05-28
MX2020001157A (es) 2022-05-27
DK3256466T3 (da) 2022-05-02
US9856238B2 (en) 2018-01-02
CN107531674B (zh) 2020-07-31
EP4046995A1 (en) 2022-08-24
CA2976095A1 (en) 2016-08-18
BR112017017354A2 (pt) 2018-04-10
PT3256466T (pt) 2022-05-10
US10336732B2 (en) 2019-07-02
US20180093974A1 (en) 2018-04-05
ES2967643T3 (es) 2024-05-03
IL253914B (en) 2021-09-30
KR20170129730A (ko) 2017-11-27
MX2017010363A (es) 2018-05-04
JP2018505205A (ja) 2018-02-22
JP7023994B2 (ja) 2022-02-22
US11192885B2 (en) 2021-12-07
AU2016219253B2 (en) 2020-10-01
SG11201706515QA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
PH12017501423A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2023001876A (es) Derivados de rapamicina.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2015012389A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors

Legal Events

Date Code Title Description
FG Grant or registration